Bevacizumab with chemotherapy provides no survival benefit for lung cancer patients
Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients – Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) ? an approach approved by the FDA in 2006 ? did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare.